Description
The NanoFET platform is a modular, adaptable scaffold for building next-generation immunotherapies. It enables rapid development of targeted treatments that bridge disease agents directly to the patient's own immune cells. The platform has several advantages, including a modular architecture, dual-function capability, adjuvant-free immune activation, and compatibility with external biologics. The market applications for this technology include oncology, infectious disease therapeutics, biodefense and military medicine, vaccine development, and pharmaceutical biologics and drug delivery.
• Modular architecture allows rapid swapping of nanobodies and peptides to address new disease targets without redesigning the core platform
• Dual-function capability bridges disease agents directly to immune cells on a single construct, enabling both targeted and broad-spectrum responses
• Adjuvant-free immune activation through self-assembling nanofibers that inherently stimulate robust, innate immune responses
• Small, stable targeting molecules (nanobodies) that are easier to produce and engineer than conventional full-size antibodies
• High-density multivalent display presents multiple antigens or functional components simultaneously, enhancing immune recognition
• Compatibility with external biologics enables partners to integrate their own AI-designed binders or proprietary targeting molecules onto the nanofiber scaffold
Attached files
Contact
Caleb Ledgerwood